当前位置： SCI文献检索 > SWISS MEDICAL WEEKLY期刊下所有文献 > Low-molecular-weight heparin in patients with renal insufficiency.

Low-molecular-weight heparin in patients with renal insufficiency.

Abstract：

BACKGROUND:Low-molecular-weight heparins (LMWH) have been shown to be safer, more effective and more convenient than unfractionated heparin (UFH) in many clinical situations. However, their use is limited in patients with renal insufficiency (RI) due to bioaccumulation. METHOD:The literature is critically reviewed and known pharmacokinetic properties are summarised. An approach to using LMWH in patients with RI is proposed on the basis of currently available evidence. RESULTS AND DISCUSSION:Pharmacokinetic data of commonly used LMWH and of UFH are summarised in respect of RI. Most data are known on enoxaparin. A dose reduction is recommended in patients with severe RI. Limited data on dalteparin and tinzaparin suggest that there is less bioaccumulation. However, further studies are needed, in respect of long-term use and clinical end-points in particular.There are no data on certoparin and only very limited data on nadroparin. A detailed approach is suggested for the use of LMWH in patients with severe RI. Briefly: (1) before using LMWH, evaluate the patient's renal function, ist expected course, imminent interventions, and general bleeding risk; (2) prefer LMWH to UFH in view of better efficacy and lower bleeding risk in general; (3) however, prefer i.v. UFH to s.c. LMWH if a patient is unstable, is awaiting emergency interventions, or has a high bleeding risk, since UFH can be stopped more quickly due to i.v. administration, has a shorter half-life time, and can be effectively antagonised; (4) prefer a well documented LMWH; use established dosing schemes; (5) monitor LMWH with peak anti-Xa levels in patients with severe RI regularly, and adjust dose to be in target range; (6) do not use LMWH in patients with severe RI if there is no possibility of measuring anti-Xa levels. CONCLUSIONS:LMWH may be considered for patients with severe RI. However, experience, judicious choice and careful monitoring of patients with severe RI treated with LMWH are necessary.

journal_name

Swiss Med Wkly

journal_title

Swiss medical weekly

authors

Schmid P,Fischer AG,Wuillemin WA

doi

smw-11284

subject

Has Abstract

pub_date

2009-08-08 00:00:00

pages

438-52

issue

31-32

eissn

1424-7860

issn

1424-3997

pii

smw-11284

journal_volume

139

pub_type

杂志文章,评审

在线工具

Low-molecular-weight heparin in patients with renal insufficiency.